Summary of the second annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling Journal Article


Authors: Holstein, S. A.; Ye, J. C.; Howard, A.; Bhutani, M.; Gormley, N.; Hahn, T.; Hillengass, J.; Krishnan, A.; Landgren, C. O.; Munshi, N. C.; Oliva, S.; Owen, R. G.; Pasquini, M. C.; Puig, N.; Weinhold, N.; Weisel, K.; McCarthy, P. L.
Article Title: Summary of the second annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Abstract: The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice. © 2018 American Society for Blood and Marrow Transplantation
Keywords: overall survival; lenalidomide; prednisone; salvage therapy; doxorubicin; cancer combination chemotherapy; conference paper; nuclear magnetic resonance imaging; clinical practice; consensus; progression free survival; bortezomib; multiple myeloma; cyclophosphamide; dexamethasone; melphalan; autologous stem cell transplantation; food and drug administration; cancer research; monoclonal antibody; blood sampling; minimal residual disease; vorinostat; immunophenotyping; open study; immune function test; united kingdom; zirconium 89; carfilzomib; hematology; clinical trial (topic); workshop; multicenter study (topic); endpoint; cancer prognosis; consolidation chemotherapy; human; daratumumab; isatuximab; immune profiling
Journal Title: Biology of Blood and Marrow Transplantation
Volume: 25
Issue: 3
ISSN: 1083-8791
Publisher: Elsevier Inc.  
Date Published: 2019-03-01
Start Page: e89
End Page: e97
Language: English
DOI: 10.1016/j.bbmt.2018.11.001
PUBMED: 30408566
PROVIDER: scopus
PMCID: PMC6445685
DOI/URL:
Notes: Source: Scopus
Altmetric Score
MSK Authors
  1. Carl Ola Landgren
    198 Landgren